ストックスクリーナーアプリを入手
150.11
0.52%
-0.78
プレマーケット:
149.94
-0.17
-0.11%
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Research Scholars Program in Solid Tumors 2026 - Oncodaily
Gilead Sciences, Inc. $GILD Stock Holdings Cut by Corient Private Wealth LP - MarketBeat
Sequoia Financial Advisors LLC Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
RSU vesting leaves Gilead (NASDAQ: GILD) CMO with 270 new shares after tax - Stock Titan
Gilead Sciences stock gains support as HSBC lifts price target to USD 175 - ad-hoc-news.de
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales - Yahoo Finance
Gilead Advances $32B U.S. Investment With New California Research Center - Business Facilities
Why is Gilead Sciences (NASDAQ:GILD) stock in focus today? - Kalkine Media
Gilead Sciences Share Price Today (GILD) | Live Chart, News & Stock Market - techgraph.co
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead Sciences, Inc. BIKTARVY ~52% U.S. HIV; HSBC PT $175 - TradingView
Gilead Sciences stock heads into the open after a 0.24% gain - ad-hoc-news.de
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Gilead Sciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: broader growth - Investing.com Nigeria
GILD Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth - MarketBeat
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage - Fierce Pharma
HSBC Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating - moomoo.com
Tidal Investments LLC Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service - MarketBeat
NICE says no to Gilead's lenacapavir for HIV PrEP - pharmaphorum
Gilead Sciences stock holds near highs as Q2 2026 EPS beats and new ex-dividend date nears - ad-hoc-news.de
Engineers Gate Manager LP Acquires Shares of 112,886 Gilead Sciences, Inc. $GILD - MarketBeat
Allworth Financial LP Sells 8,687 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock heads into the open after a 0.7 percent dip - ad-hoc-news.de
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode - MarketBeat
Gilead Sciences stock falls as investors reassess post-earnings rally - ad-hoc-news.de
Gilead launches research facility in US for new medicine development - Yahoo Finance
NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story - simplywall.st
Gilead opens new building on existing Foster City campus - NBC Bay Area
Gilead National Ribbon Cutting Ceremony - Post Register
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option - Investing.com India
Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating the Prospects with a 4.25% Potential Upside - DirectorsTalk Interviews
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Gilead Opens 182,000-Square-Foot Research Center in Foster City - Contract Pharma
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement - TradingKey
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines - Gilead Sciences
Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing - AD HOC NEWS
Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks - Moomoo
Gilead opens research center as $32 billion US build-out continues - The Pharma Letter
Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise - MarketBeat
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? - Yahoo Finance
[Press release] FDA approves Gilead’s Bixlenvo™, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens - European AIDS Treatment Group
Gilead Sciences stock gains after narrowing Q2 loss and firming 2026 guidance - AD HOC NEWS
Gilead Sciences, Inc. $GILD Holdings Raised by HighTower Advisors LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $130.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Could Gilead Sciences (NASDAQ:GILD) Remain a Nasdaq Focus? - Kalkine Media
Amundi Has $1.23 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Saudi Central Bank Acquires 41,091 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Strategically Prepares for HIV Market Changes - Intellectia AI
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative? - finance.yahoo.com
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? - AOL.com
Q&A: Gilead's Betty Chiang on what Bixlenvo means for HIV patients on complex regimens - The Pharma Letter
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill
NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
0.12%
0.04%
大文字化:
|
ボリューム (24 時間):